Metformin News and Research

RSS

Metformin is the active ingredient in a drug used to treat diabetes mellitus (a condition in which the body cannot control the level of sugar in the blood). It is also being studied in the treatment of cancer. It decreases the amount of glucose (a type of sugar) released into the bloodstream from the liver and increases the body’s use of the glucose. Metformin is a type of antidiabetic agent.

Metformin targets the gut instead of the liver to lower glucose

For decades, physicians and scientists thought metformin, the leading Type 2 diabetes medication taken by millions worldwide, mainly targets the liver to suppress glucose production.

8 May 2026

Study explains the link between NDMA-contaminated water and childhood cancer

A new study from MIT suggests that a carcinogen that has been found in medications and in drinking water contaminated by chemical plants may have a much more severe impact on children than adults.

17 Apr 2026

Study identifies new genes linked to severe pregnancy sickness

The USC research team that recently identified the hormone-encoding gene GDF15 as a key driver of pregnancy sickness has identified 9 additional genes linked to its most severe form, hyperemesis gravidarum (HG).

14 Apr 2026

Metformin protects neurons after brain injury by restoring mitochondrial health

TBI remains a major cause of death and long-term neurological disability worldwide, yet effective treatments for secondary injury are still lacking.

13 Apr 2026

Genetic variants may reduce effectiveness of popular diabetes drugs

More than a quarter of people with Type 2 diabetes take GLP-1 receptor agonists, but the popular diabetes drugs might not work as well for people who have certain genetic variants, according to a new study by Stanford Medicine scientists and their collaborators.

12 Apr 2026

Metformin boosts an exercise-linked metabolite and may help control weight in prostate cancer patients

Metformin raised the exercise-linked metabolite Lac-Phe in prostate cancer patients across disease stages and treatment settings, while Lac-Phe itself did not predict anticancer response. Patients in the BIMET-1 metformin arm also showed better weight management during anti-androgen therapy, highlighting a possible metabolic benefit relevant to prostate cancer care.

7 Apr 2026

Metformin mimics exercise-related metabolic effects in prostate cancer patients

A new study has found that metformin, a widely prescribed diabetes drug, may mimic one of exercise's core biological effects in men with prostate cancer, raising levels of a molecule tied to energy balance and weight control even when patients are inactive.

6 Apr 2026

Lifestyle care in primary clinics allows for safe diabetes deprescribing

A new research study provides real-world evidence that deprescribing glucose‑lowering medications is both feasible and safe when patients with type 2 diabetes receive lifestyle‑informed care in primary care settings.

31 Mar 2026

Antidepressant fluvoxamine reduces long COVID fatigue in clinical trial

A randomized placebo-controlled trial found that fluvoxamine, a low-cost antidepressant, reduced fatigue and improved quality of life in adults with long COVID, offering one of the first evidence-based medication options for this persistent condition. In contrast, metformin did not provide meaningful benefit for established long COVID fatigue, highlighting fluvoxamine as the more promising treatment candidate in this study.

30 Mar 2026

Researchers explore "block and lock" strategy for functional HIV cure

For millions of people living with HIV, a daily regimen of medications is a lifelong necessity. If they stop taking the drugs-commonly referred to as antiretroviral therapy-the virus usually rushes back within weeks.

23 Mar 2026

How one antibiotic dose can reshape your gut microbiome for years

Long-term registry-linked analysis of nearly 15,000 adults shows that antibiotic use is associated with persistent changes in gut microbiome diversity and composition for up to 4–8 years. These effects vary by antibiotic class, with clindamycin, fluoroquinolones, and flucloxacillin showing the strongest and most sustained associations.

17 Mar 2026

Why do some people respond better to GLP-1 drugs? Gut microbiome may hold clues

A review in the Canadian Journal of Physiology and Pharmacology examines emerging evidence linking glucagon-like peptide-1 receptor agonists (GLP-1 RAs), the gut microbiome, and obesity treatment outcomes. The authors conclude that microbiome changes seen during therapy are most likely driven by diet, behavior, and weight loss, although microbial profiling may eventually help predict patient responses.

15 Mar 2026

Postbiotics may help treat PCOS by restoring microbiome balance

Emerging studies suggest postbiotics could aid PCOS management by restoring gut microbiome balance and enhancing insulin sensitivity and hormonal regulation.

10 Mar 2026

How are GLP-1 drugs reshaping treatment for obesity, diabetes, and heart disease?

A comprehensive Lancet review synthesizes evidence from major clinical trials showing that GLP-1 receptor agonists and next-generation incretin therapies deliver substantial weight loss while reducing cardiovascular and kidney risks. Emerging dual, triple, and oral agents may further expand treatment options and improve outcomes across obesity, type 2 diabetes, and related metabolic diseases.

3 Mar 2026

ARPA-H-funded PROSPR program focuses on the biological hallmarks of aging

Columbia University Mailman School of Public Health has received an award as part of the PROactive Solutions for Prolonging Resilience (PROSPR) program within the Advanced Research Projects Agency for Health (ARPA-H) to accelerate research on the biological hallmarks of aging.

24 Feb 2026

Longevity treatments extend life but affect variation in age-at-death

A key goal in aging research is not just to extend life, but to ensure more people live longer and healthier lives with less variation in age-at-death; a concept known as "squaring the survival curve."

24 Feb 2026

Gut microbiome may shape response to GLP-1 drugs, new review suggests

This review examines how GLP-1 receptor agonists and the gut microbiome influence one another through bile acid signaling, short-chain fatty acids, and inflammatory pathways. It explores how microbial composition may shape treatment response and highlights the need for controlled human studies to enable microbiome-informed precision therapy.

19 Feb 2026

Gut bacteria patterns help predict insulin resistance in type 2 diabetes, study finds

Researchers used 16S rRNA sequencing and machine learning to identify gut microbiome patterns associated with insulin resistance severity in people with type 2 diabetes. XGBoost models showed that specific bacterial genera, including Bacteroides and Faecalibacterium, help distinguish individuals with higher insulin resistance from healthy controls.

19 Feb 2026

Metformin linked to lower odds of intermediate macular degeneration in people with diabetes

A five-year image-based study in people with type 2 diabetes found metformin use was associated with lower odds of developing intermediate age-related macular degeneration. The observational findings suggest a potential protective link but do not establish causation and warrant prospective clinical trials.

4 Feb 2026

A common diabetes drug may prevent long COVID when taken early

Research supports metformin's efficacy in reducing long COVID symptoms, suggesting its use in acute COVID-19 cases could alleviate long-term health impacts.

3 Feb 2026